WASHINGTON – The lack of detectable high-sensitivity cardiac troponin T in patients presenting with chest pain may be a marker of minimal risk of myocardial infarction within 30 days, according to...
WASHINGTON – Renal denervation’s not so simple after all.
Highly anticipated data from the large, sham-controlled renal-artery catheter denervation trial, SYMPLICITY HTN-3, gave its investigators...
WASHINGTON – The novel low-density lipoprotein cholesterol–lowering agent evolocumab took day 1 of the annual meeting of the American College of Cardiology by storm on the strength of three...
WASHINGTON – Patients with acute heart failure who were discharged on an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker were significantly less likely to be readmitted to...
WASHINGTON, D.C. – Heart failure patients discharged on inexpensive, guideline-recommended drugs were half as likely to be readmitted for the condition after 30 days, compared with those who weren’t...
A trial of aleglitazar to improve cardiovascular outcomes in patients with type 2 diabetes who had recent-onset acute coronary syndrome has been terminated early because of a lack of efficacy and an...
WASHINGTON – A first in transcatheter aortic valve replacement trials, the CoreValve prosthesis was superior to surgical valve replacement in patients with severe aortic stenosis at increased...
WASHINGTON – What can explain the failure of SYMPLICITY HTN-3? After clinical success in reducing blood pressure by 20-30 mm HG in patients with resistant hypertension, the renal denervation...
WASHINGTON – Transcatheter aortic valve replacement with the CoreValve device showed significantly higher 1-year survival than did surgical replacement, in a randomized trial of patients with severe...
